Ticker

TSXV: ITR; NYSE American: ITRG www.integraresources.com VANCOUVER, BC, April 29, 2026 /PRNewswire/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV: ITR) (NYSE American: ITRG) is pleased to announce that it has received the National Environmental Policy Act ("NEPA") Decision Record and Reclamation Permit approving its Exploration Plan of Operations (the "EPO") for the Wildcat deposit ("Wildcat" or the…

I am strongly bullish on Prenetics Global Limited, driven by the IM8 product and a successful shift to quarterly subscriptions doubling customer value. PRE's revenue is projected to grow 105.7% YoY in FY2026, with management guiding $180–$200 million, underpinned by robust international market adoption. IM8's rapid adoption fueled an 80% new customer subscription rate and increased average order value to $233,…

Prenetics Global Limited (PRE) remains a buy, with a 15% near-term and 60% 24-month upside potential based on robust revenue growth projections. PRE's strategic focus on IM8, divestiture of non-core assets, and global partnerships underpin its growth and profitability trajectory through 2027. Liquidity is strong with $100M cash and no debt, reducing dilution risk as PRE targets profitability by Q4 2027.

Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced a strategic partnership with Superpower, the preventive health platform backed by over $40 million in venture funding. The first-of-its-kind partnership connects clinical-grade…